Clik here to view.
New Generic Drug Monograph for Aztreonam
The FDA recently approved the first-time generic aztreonam (Azactam), a monobactam antibiotic for the treatment of infections caused by susceptible gram-negative organisms in adult and pediatric...
View ArticleClik here to view.
New Drug Monograph for Jevtana
The FDA recently approved the taxane antineoplastic agent Jevtana (cabazitaxel) for patients with hormone-refractory metastatic prostate cancer who have been previously treated with docetaxel. Learn...
View ArticleClik here to view.
MedWatch Safety Alert for Arava
The FDA recently announced a new boxed warning for the risk of severe liver injury associated with Arava (leflunomide), a disease-modifying antirheumatic drug (DMARD) used to treat rheumatoid arthritis...
View ArticleClik here to view.
New First-Time Generic for Enoxaparin
The FDA recently approved the first generic low molecular weight heparin enoxaparin (generic for Lovenox) for the prophylaxis and treatment of deep vein thrombosis, the prophylaxis of ischemic...
View ArticleClik here to view.
MedWatch Safety Alert for Cubicin
The FDA recently issued a communication about the risk of eosinophilic pneumonia associated with Cubicin (daptomycin), based on post-marketing adverse event reports. Patients being treated with Cubicin...
View ArticleClik here to view.
Influenza Vaccine Updates
Based on the CDC’s Advisory Committee on Immunization Practices (ACIP) recommendations for the 2010-11 season, the influenza vaccine monographs for Afluria, Agriflu, Fluarix, FluLaval, FluMist,...
View ArticleClik here to view.
MedWatch Safety Alert for Lamictal
The product labeling for Lamictal (lamotrigine) has been revised to include information about aseptic meningitis associated with the use of the drug. Lamictal is commonly used to treat seizures in...
View ArticleClik here to view.
MedWatch Safety Alert for Stalevo
The FDA recently notified healthcare professionals that patients taking Stalevo (carbidopa/levodopa/entacapone) may be at increased risk for cardiovascular events, compared to patients taking Sinemet...
View ArticleClik here to view.
New Drug Monograph for Oravig
The FDA recently approved the azole antifungal agent Oravig (miconazole) to treat oropharyngeal candidiasis in patients greater than 16 years old. Learn more at www.epocrates.com
View ArticleClik here to view.
New Indications for Saphris
The FDA recently approved two new indications for Saphris (asenapine). In addition to the acute treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar...
View ArticleClik here to view.
MedWatch Safety Alert for Valcyte
The FDA recently announced new pediatric dosing recommendations for the antiviral medication, Valcyte (valganciclovir), to help reduce the potential for overdosing children with low body weight, low...
View ArticleClik here to view.
New Dosing for Faslodex
The FDA recently approved a new dosing regimen for Faslodex (fulvestrant) based on data from CONFIRM (Comparison of Faslodex In Recurrent or Metastatic breast cancer) that demonstrated a reduction in...
View ArticleClik here to view.
New Indication for Ozurdex
The FDA recently approved a new use for the ophthalmic corticosteroid Ozurdex (dexamethasone intravitreal implant). In addition to macular edema, the drug is now indicated for posterior uveitis in...
View ArticleClik here to view.
New Drug Monograph for Gilenya
The FDA recently approved the sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adults with relapsing forms of multiple sclerosis. Learn more at www.epocrates.com
View ArticleClik here to view.
MedWatch Safety Alert for Bisphosphonates
The FDA recently advised of atypical subtrochanteric and diaphyseal femur fractures reported in patients taking bisphosphonates for osteoporosis, including Fosamax, Fosamax Plus D, Actonel, Actonel...
View ArticleClik here to view.
New Indication for Botox
The FDA recently approved the use of Botox (onabotulinumtoxinA) for the prophylaxis of headaches in adult patients with chronic migraine. Learn more at www.epocrates.com
View ArticleClik here to view.
New Drug Monograph for Pradaxa
The FDA recently approved the oral thrombin inhibitor Pradaxa (dabigatran) to prevent thromboembolic events in adult patients with atrial fibrillation. Learn more at www.epocrates.com
View ArticleClik here to view.
New Indication for Cymbalta
The FDA recently approved a new indication for the serotonin- norepinephrine reuptake inhibitor (SNRI), Cymbalta (duloxetine). In addition to treating major depressive disorder, diabetic neuropathy,...
View ArticleClik here to view.
New Indication for Vyvanse
The FDA recently approved Vyvanse (lisdexamfetamine) to treat adolescents (13-17 years old) with attention deficit hyperactivity disorder (ADHD). Vyvanse is already indicated to treat children 6-12...
View ArticleClik here to view.
New Drug Monograph for Halaven
The FDA recently approved the microtubule inhibitor Halaven (eribulin) for the treatment of metastatic breast cancer in adult patients who have previously received at least two chemotherapeutic...
View Article
